Tags:HealthDevelopmentMedTechMedicalProductDeviceBioTechDiagnosticsPharmacyDrug
Founded in 1985, Domain is a proven healthcare venture capital leader with solid investment returns from companies built to advance human health.
News
458
Team
12
Portfolio
224
References
57
Location:United States, Princeton
Member count:11-50
News 458
| Date | Title | Description |
| 21.04.2021 | Antios The... | ;MENDHAM, N.J., April 21, 2021... |
| 24.02.2020 | Antios The... | ;ATLANTA, Feb. 24, 2020 /PRNew... |
| 09.01.2020 | Omniome Cl... | ;SAN DIEGO—January 9, 2020 – O... |
| 12.12.2019 | Aspen Neur... | ;SAN DIEGO, Dec. 12, 2019 — As... |
| 09.12.2019 | Achillion ... | ;BLUE BELL, Pa., Dec. 09, 2019... |
| 11.11.2019 | Achillion ... | ;BLUE BELL, Pa., Nov. 11, 2019... |
| 25.10.2019 | Bempedoic ... | ;ANN ARBOR, Mich., Oct. 25, 20... |
| 22.10.2019 | Obalon Ann... | ;SAN DIEGO, CA, October 22, 20... |
| 21.10.2019 | Veracyte A... | ;SOUTH SAN FRANCISCO, Calif.--... |
| 17.10.2019 | Marinus Ph... | ;RADNOR, Pa., Oct. 17, 2019 (G... |
| 16.10.2019 | Alexion to... | ;BOSTON & BLUE BELL, Pa.--... |
| 11.10.2019 | FDA OKs Li... | ;Eli Lilly won FDA approval fo... |
| 07.10.2019 | Veracyte t... | ;SOUTH SAN FRANCISCO, Calif.--... |
| 03.10.2019 | Milestone ... | ;MONTREAL and CHARLOTTE, N.C.,... |
| 10.09.2019 | Milestone ... | ;MONTREAL and CHARLOTTE, N.C.,... |
| 25.06.2019 | WindMIL Th... | ;BALTIMORE, MD AND PHILADELPHI... |
| 14.05.2019 | Milestone ... | ;MONTREAL and CHARLOTTE, N.C.,... |
| 08.05.2019 | Milestone ... | ;MONTREAL and CHARLOTTE, N.C.,... |
| 06.05.2019 | Adynxx Com... | ;SAN FRANCISCO, May 06, 2019 (... |
| 16.04.2019 | Milestone ... | ;Montreal, QC, CA, and Charlot... |
| 04.04.2019 | Milestone ... | ;Montreal, QC, CA, and Charlot... |
| 19.03.2019 | Iterum The... | ;DUBLIN, Ireland and CHICAGO, ... |
| 18.09.2018 | Iterum Ini... | ;DUBLIN, Ireland and CHICAGO, ... |
| 17.09.2018 | U.S. FDA C... | ;Duluth, GA – September 17, 20... |
| 09.08.2018 | Iterum Ini... | ;DUBLIN and CHICAGO, Aug. 09, ... |
| 02.08.2018 | Celtaxsys ... | ;ATLANTA – August 2, 2018 – Ce... |
| 04.01.2018 | Celtaxsys ... | ;Atlanta, GA – (January 4, 201... |
| 24.10.2017 | Milestone ... | ;;CHARLOTTE, N.C., Oct. 24, 20... |
| 02.10.2017 | Esperion C... | ;ANN ARBOR, Mich., Oct. 02, 20... |
| 26.09.2017 | FierceBiot... | ;The philosophy of Fierce 15 i... |
| 21.08.2017 | IntegenX A... | ;;PLEASANTON, Calif.--(BUSINES... |
| 01.08.2017 | Milestone ... | ;;MONTREAL, August 1, 2017 /PR... |
| 25.07.2017 | Sebacia gr... | ;;Sebacia, which already marke... |
| 25.07.2017 | Iterum Gai... | ;;DUBLIN, IRELAND – July 25th,... |
| 29.06.2017 | FDA Grants... | ;RADNOR, Pa., June 29, 2017 (G... |
| 27.06.2017 | Marinus Ph... | ;;RADNOR, Pa., June 27, 2017 (... |
| 26.06.2017 | Esperion A... | ;;Ann Arbor, Mich., -- (Globe ... |
| 19.05.2017 | Iterum Sec... | ;DUBLIN, IRELAND, and CHICAGO ... |
| 17.05.2017 | Syndax Ann... | ;;WALTHAM, Mass., May 17, 2017... |
| 11.05.2017 | Milestone ... | ;;MONTREAL, May 11, 2017 /PRNe... |
| 11.05.2017 | FIRST EVER... | ;;CHICAGO, May 11, 2017 – Resu... |
| 27.04.2017 | ChromaCode... | ;;CARLSBAD, Calif., April 27, ... |
| 18.04.2017 | MARINUS TO... | ;;RADNOR, PA, April 18, 2017 (... |
| 12.04.2017 | Milestone ... | ;;MONTREAL, April 12, 2017 /PR... |
| 21.03.2017 | USPTO Gran... | ;NEW HAVEN, Conn., March 21, 2... |
| 20.03.2017 | Esperion A... | ;;Ann Arbor, Mich., -- (Globe ... |
| 06.03.2017 | Esperion A... | ;;ANN ARBOR, Mich., March 06, ... |
| 01.02.2017 | Marinus Ap... | ;;RADNOR, PA, February 1, 2017... |
| 25.01.2017 | Esperion C... | ;;ANN ARBOR, Mich., Jan. 25, 2... |
| 23.01.2017 | MARINUS AN... | ;;RADNOR, PA, January 23, 2017... |
| 08.01.2017 | Esperion A... | ;;Ann Arbor, Mich., -- (Globe ... |
| 05.01.2017 | Marinus Pr... | ;;RADNOR, PA, January 5, 2017 ... |
| 23.12.2016 | TWO PEER-R... | ;;SALT LAKE CITY, December 19,... |
| 01.12.2016 | Axial Biot... | ;;BOSTON, December 1, 2016 – A... |
| 30.11.2016 | Axial Biot... | ;;BOSTON, November 30, 2016 – ... |
| 28.11.2016 | Esperion T... | ;ANN ARBOR, Mich., Nov. 28, 20... |
| 20.09.2016 | Allergan t... | ;;DUBLIN and SAN FRANCISCO, Se... |
| 06.09.2016 | ROX Medica... | ;;SAN CLEMENTE, Calif., Sept. ... |
| 07.07.2016 | GENOMIC HE... | ;;REDWOOD CITY AND SAN DIEGO, ... |
| 22.06.2016 | Marinus Ph... | ;;RADNOR, Pa., June 22, 2016 (... |
| 06.06.2016 | Celator Ph... | ;;EWING, N.J., June 6, 2016 /P... |
| 31.05.2016 | JAZZ PHARM... | ;;DUBLIN and EWING, N.J., May ... |
| 19.05.2016 | Celator Ph... | ;;EWING, N.J., May 19, 2016 /P... |
| 09.05.2016 | Aldeyra Th... | ;;LEXINGTON, MA -- (Marketwire... |
| 03.05.2016 | Achillion ... | ;;NEW HAVEN, Conn., May 03, 20... |
| 21.04.2016 | Celator® P... | ;;EWING, N.J., April 21, 2016/... |
| 15.04.2016 | Marinus Ph... | ;;RADNOR, Pa., April 15, 2016 ... |
| 11.04.2016 | Syndax Ann... | ;;WALTHAM, Mass., April 11, 20... |
| 31.03.2016 | REVA MEDIC... | ;;SAN DIEGO, CALIFORNIA AND SY... |
| 31.03.2016 | Celator(R)... | ;;EWING, N.J., March 31, 2016 ... |
| 21.03.2016 | Celator(R)... | 97% over the first 24 hours), which allows the drugs to be delivered directly to leukemia cells at the synergistic 5:1 molar ratio. The trial included patients with newly diagnosed AML, relapsed/refractory AML and relapsed/refractory ALL. Responses were seen in each of the three acute leukemia patient populations. • Also in December at the ASH meeting we presented data on health resource utilization (HRU) assessments from our previously published randomized Phase 2 trial comparing first-line treatment with VYXEOS to the 7+3 regimen, in newly diagnosed older patients (age 60-75) with AML. A number of outcomes (such as fewer inductions to respond, more patients receiving consolidation on an outpatient basis, improvement in the ratio of median event-free survival days to median hospital days) were favorable for VYXEOS compared to 7+3. • In October, VYXEOS was recognized with the Nanomedicine Award 2015. This award recognizes projects or products that have been developed using innovative solutions based on nanotechnology. Technology Platform • In October, positive results were presented from our CombiPlex technology platform applied to drug combinations incorporating molecularly targeted agents (MTAs) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The successful application of this technology to molecularly targeted agents across a wide range of drug classes makes a compelling data package that we believe will be instrumental in pursuing R&D collaborations with pharmaceutical companies. General Business • In November, Celator announced it was approved to sell $1.8 million of its net operating losses and unused research and development (R&D) credits under the New Jersey Technology Business Tax Certificate Transfer Program for the year 2015, for which the company received $1.7 million in non-dilutive financing. • In November, Celator announced a notice of allowance of claims by the United States Patent and Trademark Office for the patent "Compositions for Delivery of Drug Combinations." This patent covers the Company's proprietary CombiPlex technology, and the allowed claims increase the scope of drug delivery vehicles covered by the patent.;Financial Highlights • Cash Position: Cash and cash equivalents as of December 31, 2015 were $23.3 million, compared to $32.4 million as of December 31, 2014. During the first quarter of 2016, the Company sold 1,353,900 shares of common stock through an at-the-market (ATM) equity offering program for net proceeds of $9.8 million. Management believes that the cash and cash equivalents at December 31, 2015, and the cash generated to date from sales under the ATM will be sufficient to meet estimated working capital requirements and fund planned operations into the second quarter of 2017. • R&D Expenses: Research and development expenses increased to $2.8 million for the three months ended December 31, 2015 from $2.7 million for the same period in 2014. For the year ended December 31, 2015 research and development expenses decreased to $11.8 million from $11.9 million for the same period in 2014. The full year decrease in R&D expenses was largely due to a decrease in clinical and regulatory activities during the year related to the Phase 3 trial of VYXEOS as the trial was fully enrolled, offset by an increase in expenses relating to our work on the CombiPlex platform. • G&A Expenses: General and administrative expenses increased to $1.9 million for the three months ended December 31, 2015 from $1.8 million for the same period in 2014. For the year ended December 31, 2015 general and administrative expenses increased to $7.7 million from $7.3 million for the same period in 2014. The increase was primarily attributable to increases in compensation and stock option expense, investor relations and consulting. • Net Loss: Net loss increased to $4.4 million for the three months ended December 31, 2015 from $2.4 million for same period in 2014. For the year ended December 31, 2015 net loss increased to $19.3 million from $16.9 million for the same period in 2014. The increase in net loss was primarily attributable to increased interest expense and a reduction in income tax benefit.;About Celator Pharmaceuticals, Inc. Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadening its application to include molecularly targeted therapies. For more information, please visit Celator's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.;Forward-Looking Statements: To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the safety, potential efficacy, therapeutic potential, our expectations regarding the timing of our regulatory filings and the timing of regulatory approvals, and commercial potential of VYXEOS (also known as CPX-351), the availability of data from clinical studies, our expectations regarding our research and development programs, expanding our pipeline and advancing our CombiPlex platform, our ability to pursue R&D collaborations with pharmaceutical companies and our expectation regarding the sufficiency of our working capital. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, working capital performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the regulatory process, whether the final results of our clinical studies will be supportive of regulatory approval to market VYXEOS and other matters that could affect the commercial potential of our drug candidates, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, whether clinical trial results obtained to date will be predictive of future results, our ability to raise capital and the trading of our common stock. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Celator in general, see Celator's Form 10-K for the year ended December 31, 2015 and other filings by Celator with the U.S. Securities and Exchange Commission.;CONTACTS: Media: Mike Beyer Sam Brown, Inc. 312-961-2502 mikebeyer@sambrown.com Investors: Adam Krop The Trout Group 646-378-2963 akrop@troutgroup.com">;;EWING, N.J., March 21, 2016 ... |
| 16.03.2016 | New Data S... | ;;SOUTH SAN FRANCISCO, Calif.,... |
| 14.03.2016 | Celator An... | ;;EWING, N.J., March 14, 2016 ... |
| 10.03.2016 | Landmark S... | ;;SALT LAKE CITY, March 10, 20... |
| 29.02.2016 | Aldeyra Th... | ;;LEXINGTON, Mass., February 2... |
| 23.02.2016 | CoLucid Ph... | ;;CAMBRIDGE, Mass., Feb. 23, 2... |
| 11.02.2016 | Achillion ... | ;;NEW HAVEN, Conn., Feb. 11, 2... |
| 21.01.2016 | INTERNATIO... | ;;LAGUNA HILLS, Calif.--(BUSIN... |
| 21.01.2016 | Five Prime... | .;Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements about the (i) use of FPA144 in other indications outside of gastric cancer; (ii) evaluation of FPA144 as a monotherapy in refractory gastric cancer; and (iii) percent of gastric cancer patients whose tumors are FGFR2 gene-amplified. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or lower than expected FGFR2 gene amplification rates observed during additional preclinical or clinical studies of FPA144. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.">;;SOUTH SAN FRANCISCO, Calif.,... |
| 20.01.2016 | Allan L. S... | ;;WALTHAM, Mass., Jan. 20, 201... |
| 13.01.2016 | Esperion T... | and follow us on Twitter at https://twitter.com/EsperionInc |
| 12.01.2016 | Esperion T... | ;;ANN ARBOR, Mich., Jan. 12, 2... |
| 11.01.2016 | Achaogen A... | ;;SOUTH SAN FRANCISCO, CA, USA... |
| 11.01.2016 | Five Prime... | .">;;SOUTH SAN FRANCISCO, Calif.,... |
| 11.01.2016 | Celator(R)... | ;;EWING, N.J., Jan. 11, 2016 /... |
| 07.01.2016 | Tobira The... | ;;SOUTH SAN FRANCISCO, Calif.,... |
| 07.01.2016 | Veracyte A... | .;Cautionary Note Regarding Forward-Looking Statements;This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our beliefs regarding the drivers of adoption of Afirma, our expectations with respect to the success of our entry into the pulmonology market, our expectations regarding full-year 2015 guidance and forecast for annual GEC test volume, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our limited operating history and history of losses; our ability to increase usage of and reimbursement for Afirma and to obtain reimbursement for any future products we may develop or sell; our ability to continue our momentum and growth; our dependence on a few payers for a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our tests; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our dependence on strategic relationships and our ability to successfully convert new accounts resulting from such relationships; our ability to develop and commercialize new products and the timing of commercialization; our ability to successfully achieve adoption of and reimbursement for our Percepta Bronchial Genomic Classifier; our ability to achieve sales penetration in complex commercial accounts; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; our ability to compete; our ability to expand into international markets and achieve adoption of our tests in such markets; our ability to obtain capital when needed; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.">;;SOUTH SAN FRANCISCO, Calif.,... |
| 05.01.2016 | BioNano Ge... | ;;SAN DIEGO, Jan. 05, 2016 (GL... |
| 04.01.2016 | Merck KGaA... | ;;Darmstadt, Germany, New York... |
| 17.12.2015 | Navihealth... | ;Navihealth Acquires Rightcare... |
| 15.12.2015 | Alimera Sc... | ;ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant approved in the U.S. to treat diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Each ILUVIEN implant is designed to release submicrogram levels of fluocinolone acetonide (FAc), a corticosteroid, for 36 months.;Corticosteroids have a history of effective use in treating ocular disease inflammation. ILUVIEN is injected in the back of the patient's eye with an applicator that employs a 25-gauge needle, which allows for a self-sealing wound. In the FAME™ Study, a phase 3 clinical study of ILUVIEN, the primary endpoint of improvement in vision of 15 letters or more was demonstrated at 24 months and the most frequently reported adverse drug reactions included cataract development and increased ocular pressure.;About Diabetic Macular Edema (DME);DME, the primary cause of vision loss associated with diabetic retinopathy, is a disease affecting the macula, the part of the retina responsible for central vision. When the blood vessel leakage associated with diabetic retinopathy results in swelling of the macula, the condition is called DME. The onset of DME is painless and may go unreported by the patient until it manifests with the blurring of central vision or acute vision loss. The severity of this blurring may range from mild to profound loss of vision. According to the International Diabetes Foundation's Diabetes Atlas Sixth Edition, Update 2014, the comparative prevalence of diabetes in the countries covered by the agreement with MEAgate ranges from 8% to 24% of the population.;About MEAgate International FZ LCC;The management team of MEAgate are seasoned pharmaceutical and life sciences executives with over 35 years combined experience in selling pharmaceuticals and medical devices in much of the Middle East. They have developed a Middle East hub to address the needs of small to medium innovative companies, and become the partner of choice that ensures highest scientific and compliant standards while managing - on behalf of the company - a network of carefully chosen country distributors. Teams are centrally selected, hired and trained, ensuring that the same high standards are applied across the region.;About Alimera Sciences, Inc.;www.alimerasciences.com |
| 14.12.2015 | Veracyte A... | .">;;SOUTH SAN FRANCISCO, Calif.,... |
| 11.12.2015 | Otonomy An... | ;;SAN DIEGO, Dec. 11, 2015 (GL... |
| 08.12.2015 | Tobira The... | 25 kg/m2 with at least one metabolic syndrome criterion. • The majority of the subjects have type 2 diabetes (52.9%). With respect to liver histology characteristics: • The majority of subjects have a NAS > 5 (74.0%) and moderate-to-severe fibrosis, i.e. NASH CRN stage 2-3 (66.8%). • Subjects have a total mean NAFLD Activity Score (NAS) of 5.3 (SD 1.03) with mean scores of 1.5 (SD 0.50) for hepatocellular ballooning, 1.4 (SD 0.57) for steatosis and 2.4 (SD 0.57) for lobular inflammation. • CCR2/CCR5 Antagonism with Cenicriviroc Decreases Fibrosis Scores in HIV-Infected Patients. Authors: KE Sherman, E Abdel-Hameed and SD Rouster In this 48-week randomized, double-blind, active comparator Phase 2b study, serum samples from 143 HIV patients were evaluated by an independent group using the enhanced liver fibrosis (ELF) index. Patients were randomized to receive cenicriviroc or efavirenz (control group) with backbone of tenofovir/emtricitabine. Baseline and 48-week serum samples from the study cohort were evaluated using the ELF Index. The ELF Index, which measures key hepatic fibrosis and collagen biomarkers (Procollagen III, TIMP-1, and Hyaluronic Acid) was validated by independent comparison with liver biopsy findings in a separate group of subjects and then applied to the HIV study subjects. After validation, the ELF index was then used to determine fibrosis scores in 36 subjects treated with CVC 200 mg for 48 weeks versus 16 subjects treated with efavirenz for 48 weeks. • The mean ELF Index at baseline in the CVC group was 10.53 (SD 2.12) and was 9.13 (SD 0.99) in the efavirenz group. • After 48 weeks of treatment, the mean ELF index significantly decreased to 8.28 (SD 0.88) in the CVC group (p < 0.0001) but not in the efavirenz group. Oral Presentation Cenicriviroc: A Novel Agent Targeting Immuno-Inflammatory Pathways for the Treatment of NASH with Liver Fibrosis. Presenter: E Lefebvre, Tobira Therapeutics In this presentation, the author will highlight the pre-clinical and clinical translational evidence for the use of CVC in treating subjects diagnosed with NASH and liver fibrosis. Additionally, the innovative design of the CENTAUR study and the baseline characteristics of subjects enrolled will be described. About Cenicriviroc (CVC) and Non-alcoholic Steatohepatitis (NASH) CVC is an oral, once-daily, potent immunomodulator that blocks two chemokine receptors, CCR2 and CCR5, which are intricately involved in the inflammatory and fibrogenic pathways in NASH that cause liver damage and often lead to cirrhosis, liver cancer or liver failure. Tobira believes this novel approach will establish CVC as both a single-agent and as a cornerstone treatment in multi-therapy regimens for NASH, for which there is currently no approved drug. CVC is currently being evaluated in Tobira's fully enrolled global Phase 2b CENTAUR study (identifier NCT02217475) and the company expects to announce the study's primary endpoint in the third quarter of 2016. CENTAUR is comparing CVC to placebo in 289 patients with NASH and liver fibrosis. CVC has been granted Fast Track status in patients with NASH and liver fibrosis, the patient population at highest risk of progression to cirrhosis. The CENTAUR study includes surrogate endpoints identified as suitable for registrational studies in findings of an FDA-AASLD workshop reported in Hepatology. To date, approximately 600 subjects have been dosed in completed studies with CVC, including 115 HIV infected subjects on treatment for up to 48 weeks. NASH is an emerging health crisis impacting 3% to 5% of the U.S. population and 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. Additionally, this population is estimated to be three to five times larger than the size of the population with hepatitis C in the U.S.;About Tobira Therapeutics Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and HIV. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). Learn more about Tobira at www.tobiratherapeutics.com.;Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.;©2015 Tobira Therapeutics, Inc. All Rights Reserved.;Forward Looking Statements This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the company's clinical development of cenicriviroc (CVC), the potential timing and outcomes of clinical studies of CVC undertaken now or in the future; the ability of the company to timely source adequate supply of its development products from third party manufacturers on whom the company depends; the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all; the company's ability to successfully progress, partner or complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect its intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's filings with the Securities and Exchange Commission.;Tobira Investor & Media Contact: Ian Clements, Ph.D. +1 (650) 351-5013 ir@tobiratherapeutics.com;Canale Communications Media Contact: Pam Lord +1 (619) 849-6003 pam@canalecomm.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tobira-therapeutics-announces-data-presentations-highlighting-cenicriviroc-at-hep-dart-2015-300189894.html SOURCE Tobira Therapeutics, Inc.">;;SOUTH SAN FRANCISCO, Calif.,... |
| 08.12.2015 | Afferent P... | ;;December 08, 2015 08:00 AM E... |
| 07.12.2015 | Neothetics... | .;Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks ofNeothetics, Inc. Other names and brands may be claimed as the property of others.">;;SAN DIEGO, Dec. 7, 2015 (GLO... |
| 06.12.2015 | Atara Bio ... | ;;SOUTH SAN FRANCISCO, Calif.,... |
| 03.12.2015 | Syndax Ann... | ;;WALTHAM, Mass., Dec. 3, 2015... |
| 01.12.2015 | Syndax Ann... | ;;WALTHAM, Mass., Dec. 1, 2015... |
| 01.12.2015 | Epic Scien... | ;;SAN DIEGO, Dec. 1, 2015 /PRN... |
| 30.11.2015 | CoLucid Ph... | ;;CAMBRIDGE,MA – November 30, ... |
Show more
Team 12
| Date | Name | Title | Description |
| - | Scott Borg... | IT Directo... | ;Scott joined Domain as IT dir... |
| - | Brian Dove... | Partner | ;Brian has been a partner of D... |
| - | Jesse Treu... | Partner Em... | ;Jesse was a founding partner ... |
| - | Leena Gand... | Senior Acc... | ;Leena joined Domain in 2000 a... |
| - | Jim Blair,... | Partner | ;Jim has been a partner of Dom... |
| - | Nicole Vit... | Partner | ;Nicole joined Domain in 1999 ... |
| - | Kim Kamdar... | Partner | ;Kim joined Domain in 2005 and... |
| - | Kathleen S... | Partner &a... | ;Kathleen joined Domain at its... |
| - | Lisa Kraeu... | Managing D... | ;Lisa joined Domain as control... |
| - | Brian Hala... | Partner | ;Brian Halak, Ph.D. has been c... |
| - | Eckard Web... | Advisory P... | ;Eckard joined Domain in 2001 ... |
| - | Dennis Pod... | Advisory P... | ;Dennis joined Domain as a par... |
Show more
Portfolio 224
| Date | Name | Description | Website |
| - | Medico (Ho... | Chinese affiliate of Smart Med... | - |
| - | Verus Phar... | Development and marketing of p... | - |
| - | VentiRx Ph... | Developing novel drugs for the... | ventirx.co... |
| - | SkinMedica... | Acquires & markets dermato... | skinmedica... |
| - | Iterum The... | Developing differentiated anti... | iterumtx.c... |
| - | Cadent Med... | Life-saving external defibrill... | - |
| - | Cabrellis ... | Development of important thera... | - |
| - | Univax Bio... | Vaccines to stimulate the plas... | - |
| - | Novadigm T... | Developing vaccines and therap... | novadigm.n... |
| - | Santarus, ... | GI drug development using nove... | - |
| - | Celator Ph... | Development of proprietary fix... | celatorpha... |
| - | Geron Corp... | Discovery of mechanisms and th... | geron.com/ |
| - | Sequent Me... | Dedicated to the development o... | sequentmed... |
| - | Colorescie... | Markets products which fuse th... | colorescie... |
| - | Celladon C... | Developing treatments for card... | - |
| - | Nanothera ... | Developing safer parenteral pr... | - |
| - | Dura Pharm... | Specialty pharmaceutical compa... | - |
| - | Applied Bi... | Technology solutions for DNA, ... | appliedbio... |
| - | Konova, In... | Anti-obesity drug development | - |
| - | Ascenta Th... | Anti-cancer drug development | - |
| - | US Bioscie... | Acquisition and marketing of c... | - |
| - | Zyga Techn... | Developing therapies for the t... | zyga.com/ |
| - | Amylin Pha... | Development of drugs to treat ... | - |
| - | Aurora Bio... | Automation to facilitate drug ... | - |
| - | Miramar La... | Developing devices for aesthet... | miramarlab... |
| - | Exalys The... | Developing a family of EP4 Ant... | exalystx.c... |
| - | Auxeris Th... | Osteoporosis drug development | - |
| - | Pharmion C... | Acquires and markets hematolog... | - |
| - | Epic Scien... | Developing new diagnostics for... | epicscienc... |
| - | Omniome, I... | Developing a novel approach to... | omniome.co... |
| - | Sievers In... | Novel detectors for gas chroma... | - |
| - | Biomagneti... | Instrumentation for ultra-sens... | - |
| - | Small Mole... | Discovery of small molecule dr... | - |
| - | Evoke Phar... | Acquisition and development of... | evokepharm... |
| - | Resound Co... | Revolutionary technology for h... | - |
| - | Novalar Ph... | Development of dental medicati... | - |
| - | Singular G... | Next generation sequencing com... | singularge... |
| - | RightCare ... | An evidence-based technology c... | rightcares... |
| - | GenVault C... | High capacity DNA storage syst... | - |
| - | X-Ceptor T... | Drug development focused on or... | - |
| - | Iomai Corp... | Transdermal vaccines | - |
| - | Inspire Ph... | Drug development for ophthalmi... | - |
| - | Antios The... | Late-stage pre-clinical compan... | antiosther... |
| - | Achaogen, ... | Pursuing unique strategies to ... | achaogen.c... |
| - | Microgon I... | Hollow-fiber membrane filters ... | - |
| - | Orqis Medi... | Device to treat congestive hea... | - |
| - | MicroVenti... | Interventional neurology devic... | microventi... |
| - | Benvenue M... | Developing devices for the tre... | benvenueme... |
| - | Somaxon Ph... | Development of psychiatric dru... | - |
| - | Calixa The... | Focused on developing, acquiri... | - |
| - | Otonomy, I... | Developing novel drug therapie... | otonomy.co... |
| - | Tandem Dia... | Developing novel devices for t... | tandemdiab... |
| - | Marinus Ph... | Development of therapeutics fo... | marinuspha... |
| - | Xcel Pharm... | Acquires & markets neurolo... | - |
| - | Regado Bio... | Developing rapidly reversible ... | - |
| - | Atara Biot... | Developing novel treatment opt... | atarabio.c... |
| - | TargetRx, ... | Information services for the p... | - |
| - | GenQuest, ... | Gene identification for diagno... | - |
| - | NPS Pharma... | Development of drugs for bone,... | - |
| - | Alimera Sc... | Development and marketing of i... | alimerasci... |
| - | IntegenX I... | Developing equipment for molec... | integenx.c... |
| - | ROX Medica... | Device to treat chronic obstru... | - |
| - | Receptor B... | Developing a new class of prot... | - |
| - | Vivus, Inc... | Therapeutics to treat sexual d... | vivus.com/ |
| - | Cartiva, I... | Development of medical devices... | cartiva.ne... |
| - | Volcano Co... | Detection and treatment of vas... | volcanocor... |
| - | Evofem Bio... | Developing a portfolio of ther... | evofem.com... |
| - | Connetics ... | Development and marketing of d... | - |
| - | Sequel Pha... | Cardiovascular drug developmen... | - |
| - | NovaCardia... | Cardiovascular drug developmen... | - |
| - | RiboGene, ... | Therapeutics based on control ... | - |
| - | aTyr Pharm... | Developing Physiocrines, a nov... | atyrpharma... |
| - | CardioPoly... | Novel therapies for diseases o... | - |
| - | Senomyx, I... | Discovery and development of f... | senomyx.co... |
| - | Eddingphar... | Marketing oncology products in... | eddingphar... |
| - | CoCensys, ... | Development of CNS drugs targe... | - |
| - | Vascular A... | Novel stent technology | - |
| - | Glaukos Co... | Device to treat glaucoma | glaukos.co... |
| - | LaJolla Ph... | Development of therapeutics fo... | ljpc.com/ |
| - | Ista Pharm... | Drug development for ophthalmi... | - |
| - | REVA Medic... | Resorbable stent technology | teamreva.c... |
| - | NeuroPace,... | Device to treat epilepsy | neuropace.... |
| - | Corridor P... | Developing therapeutics for va... | - |
| - | GI Dynamic... | Device to treat obesity | gidynamics... |
| - | Apnex Medi... | Developing a device-based trea... | - |
| - | Cantex Pha... | Developing a proprietary, modi... | cantex.com... |
| - | Fractyl He... | Developing device based treatm... | fractyl.co... |
| - | Ruxton Pha... | Proprietary assays to discover... | - |
| - | Conforma T... | Anti-cancer drug development | - |
| - | Cardiac Sc... | Life-saving external defibrill... | cardiacsci... |
| - | Durata The... | Development of Dalbavancin, a ... | duratather... |
| - | IntraLase ... | Devices for laser correction o... | - |
| - | Cortria Co... | Developing safe and well-toler... | - |
| - | BiPar Scie... | Developing and commercializing... | - |
| - | Ocunexus T... | Development and commercializat... | ocunexus.c... |
| - | Immune Con... | Developing drugs to stop undes... | - |
| - | Gensia Pha... | Development of drugs to treat ... | - |
| - | Proxima Th... | Novel system to deliver radiat... | - |
| - | Axial Ther... | Developing a new class of ther... | axialtx.co... |
| - | Aesthetic ... | Focused on aesthetic medicine ... | - |
| - | ProteinSim... | Lab instrumentation enabling a... | proteinsim... |
Show more
Mentions in press and media 57
| Date | Title | Description | Category | Author | Source |
| 20.11.2019 | With echoe... | A little over a year after the... | Apple, col... | Jonathan S... | techcrunch... |
| 01.08.2017 | Tekla Capi... | Milestone Pharmaceuticals Mont... | - | - | citybizlis... |
| 01.08.2017 | Domain Ass... | Milestone Pharmaceuticals Mont... | - | - | citybizlis... |
| 25.07.2017 | Domain Ass... | Sebacia, Inc., a privately hel... | - | - | citybizlis... |
| 21.05.2017 | Iterum Rai... | Iterum Therapeutics Limited, a... | - | - | citybizlis... |
| 21.05.2017 | Domain Ass... | Iterum Therapeutics Limited, a... | - | - | citybizlis... |
| 30.04.2017 | Domain Ass... | Epic Sciences (Epic) announced... | - | - | citybizlis... |
| 27.04.2017 | Domain Ass... | ChromaCode, Inc., a molecular ... | - | - | citybizlis... |
| 27.04.2017 | NEA Leads ... | ChromaCode, Inc., a molecular ... | - | - | citybizlis... |
| 09.12.2016 | Term Sheet... | Layoff Watch and Founder-Frien... | - | - | fortune.co... |
| 09.12.2016 | Domain Ass... | Domain Associates, a San Diego... | USA | - | finsmes.co... |
| 19.11.2015 | Daily fund... | PresenceLearning raised $25M; ... | - | Mitos Suso... | vator.tv/n... |
| 24.10.2015 | A look at ... | 1. Genetic testing turns quick... | - | - | medcitynew... |
| 20.10.2015 | Watch out,... | Given the recent focus on sing... | - | - | medcitynew... |
| 10.07.2015 | Xagenic Ra... | Xagenic, a Toronto, Canada-bas... | Canada | - | finsmes.co... |
| 17.09.2014 | RightCare ... | In addition to Murphy, other m... | - | - | medcitynew... |
| 04.09.2014 | Fractyl La... | Fractyl Laboratories, a Waltha... | USA | - | finsmes.co... |
| 18.06.2014 | Benvenue M... | InterWest Partners led the rou... | - | - | medcitynew... |
| 11.12.2013 | Domain VC:... | Some firms have pulled back on... | - | - | medcitynew... |
| 02.12.2013 | Xagenic Cl... | Xagenic Inc., a Toronto, Canad... | Canada fu... | - | finsmes.co... |
| 13.11.2013 | Health IT ... | Last year, Right Care netted $... | - | - | medcitynew... |
| 04.11.2013 | Healthcare... | Anti-VEGF therapy proved to be... | - | - | medcitynew... |
| 04.10.2013 | $14M round... | The vaccine contains a recombi... | - | - | medcitynew... |
| 03.10.2013 | NovaDigm T... | NovaDigm Therapeutics, a Grand... | funding S... | - | finsmes.co... |
| 29.07.2013 | Domain's $... | PRINCETON, N.J. and SAN DIEG... | - | - | domainvc.c... |
| 29.07.2013 | Domain... | San Diego-based venture invest... | - | - | socaltech.... |
| 12.06.2013 | Domain... | San Diego-based biotech invest... | - | - | socaltech.... |
| 25.04.2013 | Esperion T... | Share Share on Facebook Share ... | - | Sarah Schm... | xconomy.co... |
| 25.04.2013 | Esperion T... | Esperion Therapeutics, Inc., a... | funding U... | - | finsmes.co... |
| 16.04.2013 | Why digita... | Paul Sonnier is Head of Digita... | - | - | venturebea... |
| 19.12.2012 | Biopharma ... | Other treatment programs in it... | - | - | medcitynew... |
| 19.12.2012 | Domain... | San Diego-based venture capita... | - | - | socaltech.... |
| 13.11.2012 | Epic Scien... | Epic Sciences, Inc., a San Die... | funding S... | - | finsmes.co... |
| 13.11.2012 | Cancer dia... | “Epic’s technology has achieve... | - | - | medcitynew... |
| 11.10.2012 | Discharge ... | The Fort Washington, Pennsylva... | - | - | medcitynew... |
| 03.10.2012 | Biotech co... | Solution/Product: The company ... | - | - | medcitynew... |
| 08.03.2012 | Morning Re... | Doctors say that investing tim... | - | - | medcitynew... |
| 18.01.2012 | Carticept ... | Carticept Medical, Inc., an Al... | funding U... | - | finsmes.co... |
| 09.01.2012 | Aria Diagn... | Aria Diagnostics (formerly kno... | funding S... | - | finsmes.co... |
| 30.12.2011 | Celator Ph... | The Celator’s approach to canc... | - | - | medcitynew... |
| 15.11.2011 | Sera Progn... | Sera Prognostics Inc., a Salt ... | funding U... | - | finsmes.co... |
| 22.02.2011 | Early stag... | Promoted Clinical Care Capaci... | - | - | medcitynew... |
| 03.06.2010 | Apnex taps... | By Thomas Lee Apnex Medical I... | - | MedCity Ne... | massdevice... |
| 02.06.2010 | Apnex Medi... | Promoted Covid-19’s terrible ... | - | - | medcitynew... |
| 10.08.2009 | Domain Ass... | Promoted This Patient Experie... | - | - | medcitynew... |
| 20.07.2009 | Oraya scor... | Oraya Therapeutics, maker of r... | - | - | venturebea... |
| 16.06.2009 | SkinMedica... | SkinMedica, maker of specializ... | - | - | venturebea... |
| 15.04.2009 | Cancer dru... | BiPar Sciences, maker of tumor... | - | - | venturebea... |
| 13.04.2009 | Philanthro... | Legacy Venture, the Palo Alto,... | - | - | venturebea... |
| 10.04.2009 | Cell Biosc... | Cell Biosciences announced tha... | - | - | venturebea... |
| 09.04.2009 | Investors ... | After failing to raise a susta... | - | - | venturebea... |
| 18.02.2009 | Public bio... | Much has been written about ho... | - | - | venturebea... |
| 14.01.2009 | Corthera a... | Pharmaceutical company Corther... | - | - | venturebea... |
| 13.01.2009 | BiPar snag... | Pharmaceutical firm BiPar Scie... | - | - | venturebea... |
| 09.01.2009 | Achaogen t... | Pharmaceutical company Achaoge... | - | - | venturebea... |
| 29.10.2008 | BioLogix b... | Biopharm company BioLogix rais... | - | - | venturebea... |
| 15.05.2007 | Apnex Medi... | Apnex Medical, a Minneapolis m... | - | - | venturebea... |
Show more